Paradoxical effects of short- and long-term interleukin-6 exposure on liver injury and repair

Hepatology

Volumn 43, Issue 3, 2006, Pages 474-484

  Jin, Xiaoling ^a   Zimmers, Teresa A ^a   Perez, Eduardo A ^a   Pierce, Robert H ^b   Zhang, Zongxiu ^a   Koniaris, Leonidas G ^a,c  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^c UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; CASPASE 9; CYTOCHROME C; FAS ANTIGEN; INTERLEUKIN 6; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN JO2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEATH; CHO CELL; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; LIVER FAILURE; LIVER INJURY; LIVER PROTECTION; LIVER REGENERATION; MITOCHONDRION; MOUSE; NONHUMAN; NUDE MOUSE; OSMOTIC MINIPUMP; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION;

ANIMALS; ANTIGENS, CD95; APOPTOSIS; BCL-ASSOCIATED DEATH PROTEIN; BCL-X PROTEIN; CASPASE 9; CASPASES; CHO CELLS; CRICETINAE; CRICETULUS; FEMALE; HEPATECTOMY; INTERLEUKIN-6; LIVER; LIVER REGENERATION; MICE; MICE, INBRED C57BL; MICE, NUDE; MITOCHONDRIA, LIVER; RECOMBINANT PROTEINS; WOUND HEALING;

EID: 33645218763     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21087     Document Type: Article

References (42)

1. Van Snick J. Interleukin-6: an overview. Annu Rev Immunol 1990;8:253-278.
2. Zimmers TA, Davies MV, Koniaris LG, Haynes P, Esquela AF, Tomkinson KN, et al. Induction of cachexia in mice by systemically administered myostatin. Science 2002;296:1486-1488.
3. Streetz KL, Luedde T, Manns MP, Trautwein C. Interleukin 6 and liver regeneration. Gut 2000;47:309-312.
4. Yamada Y, Kirillova I, Peschon JJ, Fausto N. Initiation of liver growth by tumor necrosis factor: deficient liver regeneration in mice lacking type I tumor necrosis factor receptor. Proc Natl Acad Sci U S A 1997;94:1441-1446.
5. Kovalovich K, Li W, DeAngelis R, Greenbaum LE, Ciliberto G, Taub R. Interleukin-6 protects against Fas-mediated death by establishing a critical level of anti-apoptotic hepatic proteins FLIP, Bcl-2, and Bcl-xL. J Biol Chem 2001;276:26605-26613.
6. Sakamoto T, Liu Z, Murase N, Ezure T, Yokomuro S, Poli V, Demetris AJ. Mitosis and apoptosis in the liver of interleukin-6-deficient mice after partial hepatectomy. HEPATOLOGY 1999;29:403-411.
7. Hong F, Kim WH, Tian Z, Jaruga B, Ishac E, Shen X, et al. Elevated interleukin-6 during ethanol consumption acts as a potential endogenous protective cytokine against ethanol-induced apoptosis in the liver: involvement of induction of Bcl-2 and Bcl-x(L) proteins. Oncogene 2002;21:32-43.
8. El Assal O, Hong F, Kim WH, Radaeva S, Gao B. IL-6 deficient mice are susceptible to ethanol-induced hepatic steatosis: IL-6 protects against ethanol-induced oxidative stress and mitochondrial permeability transition in the liver. Cell Mol Immunol 2004;1:205-211.
9. Martinez OM, Krams SM, Sterneck M, Villanueva JC, Falco DA, Ferrell LD, et al. Intragraft cytokine profile during human liver allograft rejection. Transplantation 1992;53:449-456.
10. Hill DB, Marsano L, Cohen D, Allen J, Shedlofsky S, McClain CJ. Increased plasma interleukin-6 concentrations in alcoholic hepatitis. J Lab Clin Med 1992;119:547-552.
11. Diehl AM. Cytokines and the molecular mechanisms of alcoholic liver disease. Alcohol Clin Exp Res 1999;23:1419-1424.
12. Laso FJ, Iglesias-Osma C, Ciudad J, Lopez A, Pastor I, Orfao A. Chronic alcoholism is associated with an unbalanced production of Th-1/Th-2 cytokines by peripheral blood T cells. Alcohol Clin Exp Res 1999;23:1306-1311.
13. Torbenson M, Yang SQ, Liu HZ, Huang J, Gage W, Diehl AM. STAT-3 overexpression and p21 up-regulation accompany impaired regeneration of fatty livers. Am J Pathol 2002;161:155-161.
14. Zimmers TA, McKillop IH, Pierce RH, Yoo JY, Koniaris LG. Massive liver growth in mice induced by systemic interleukin 6 administration. HEPATOLOGY 2003;38:326-334.
15. Lukashevich IS, Tikhonov I, Rodas JD, Zapata JC, Yang Y, Djavani M, et al. Arenavirus-mediated liver pathology: acute lymphocytic choriomeningitis virus infection of rhesus macaques is characterized by high-level interleukin-6 expression and hepatocyte proliferation. J Virol 2003;77:1727-1737.
16. Peters M, Blinn G, Jostock T, Schirmacher P, Meyer zum Buschenfelde KH, Galle PR, et al. Combined interleukin-6 and soluble interleukin-6 receptor accelerates murine liver regeneration. Gastroenterology 2000;119:1663-1671.
17. Sheron N, Bird G, Goka J, Alexander G, Williams R. Elevated plasma interleukin-6 and increased severity and mortality in alcoholic hepatitis. Clin Exp Immunol 1991;84:449-453.
18. Sheron N, Lau JN, Hofmann J, Williams R, Alexander GJ. Dose-dependent increase in plasma interleukin-6 after recombinant tumour necrosis factor infusion in humans. Clin Exp Immunol 1990;82:427-428.
19. Yang SQ, Lin HZ, Mandal AK, Huang J, Diehl AM. Disrupted signaling and inhibited regeneration in obese mice with fatty livers: implications for nonalcoholic fatty liver disease pathophysiology. HEPATOLOGY 2001;34:694-706.
20. Wuestefeld T, Rakemann T, Kubicka S, Manns MP, Trautwein C. Hyperstimulation with interleukin 6 inhibits cell cycle progression after hepatectomy in mice. HEPATOLOGY 2000;32:514-522.
21. Higgins GM, Anderson RM. Experimental pathology of the liver I. Restoration of the liver of the white rat following partial surgical removal. Arch Pathol 1931;12:186-202.
22. Koniaris LG, McKillop IH, Schwartz SI, Zimmers TA. Liver regeneration. J Am Coll Surg 2003;197:634-659.
23. Zimmers TA, Pierce RH, McKillop IH, Koniaris LG. Resolving the role of IL-6 in liver regeneration. HEPATOLOGY 2003;38:1590-1591; author reply 1591.
24. Taub R. Hepatoprotection via the IL-6/Stat3 pathway. J Clin Invest 2003;112:978-980.
25. Haga S, Terui K, Zhang HQ, Enosawa S, Ogawa W, Inoue H, et al. Stat3 protects against Fas-induced liver injury by redox-dependent and -independent mechanisms. J Clin Invest 2003;112:989-998.
26. Xanthoudakis S, Miao GG, Curran T. The redox and DNA-repair activities of Ref-1 are encoded by nonoverlapping domains. Proc Natl Acad Sci U S A 1994;91:23-27.
27. Yoo YH, Lim YJ, Park SE, Kim JM, Park YC. Overexpression of redox factor-1 negatively regulates NO synthesis and apoptosis in LPS-stimulated RAW 264.7 macrophages. FEBS Lett 2004;556:39-42.
28. Angkeow P, Deshpande SS, Qi B, Liu YX, Park YC, Jeon BH, et al. Redox factor-1: an extra-nuclear role in the regulation of endothelial oxidative stress and apoptosis. Cell Death Differ 2002;9:717-725.
29. Peter ME. The flip side of FLIP. Biochem J 2004;382:e1-3.
30. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell 2004;116:205-219.
31. Susin SA, Lorenzo HK, Zamzami N, Marzo I, Snow BE, Brothers GM, et al. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 1999;397:441-446.
32. Selzner N, Selzner M, Tian Y, Kadry Z, Clavien PA. Cold ischemia decreases liver regeneration after partial liver transplantation in the rat: A TNF-alpha/IL-6-dependent mechanism. HEPATOLOGY 2002;36:812-818.
33. Sun Z, Klein AS, Radaeva S, Hong F, El-Assal O, Pan HN, et al. In vitro interleukin-6 treatment prevents mortality associated with fatty liver transplants in rats. Gastroenterology 2003;125:202-215.
34. Selzner M, Camargo CA, Clavien PA. Ischemia impairs liver regeneration after major tissue loss in rodents: protective effects of interleukin-6. HEPATOLOGY 1999;30:469-475.
35. Hong F, Radaeva S, Pan HN, Tian Z, Veech R, Gao B. Interleukin 6 alleviates hepatic steatosis and ischemia/reperfusion injury in mice with fatty liver disease. HEPATOLOGY 2004;40:933-941.
36. Senn JJ, Klover PJ, Nowak IA, Zimmers TA, Koniaris LG, Furlanetto RW, et al. Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem 2003;278:13740-13746.
37. Klover PJ, Zimmers TA, Koniaris LG, Mooney RA. Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes 2003;52:2784-2789.
38. Chen NL, Bai L, Li L, Chen PL, Zhang C, Liu CY, et al. Apoptosis pathway of liver cells in chronic hepatitis. World J Gastroenterol 2004;10:3201-3204.
39. Walsh MJ, Vanags DM, Clouston AD, Richardson MM, Purdie DM, Jonsson JR, et al. Steatosis and liver cell apoptosis in chronic hepatitis C: a mechanism for increased liver injury. HEPATOLOGY 2004;39:1230-1238.
40. Ehrmann J Jr., Galuszkova D, Ehrmann J, Krc I, Jezdinska V, Vojtesek B, et al. Apoptosis-related proteins, BCL-2, BAX, FAS, FAS-L and PCNA in liver biopsies of patients with chronic hepatitis B virus infection. Pathol Oncol Res 2000;6:130-135.
41. Messaris E, Antonakis PT, Memos N, Chatzigianni E, Leandros E, Konstadoulakis MM. Deferoxamine administration in septic animals: improved survival and altered apoptotic gene expression. Int Immunopharmacol 2004;4:455-459.
42. Campbell JS, Prichard L, Schaper F, Schmitz J, Stephenson-Famy A, Rosenfeld ME, et al. Expression of suppressors of cytokine signaling during liver regeneration. J Clin Invest 2001;107:1285-1292.